Search

Your search keyword '"Bunin, Nancy"' showing total 705 results
Start Over Author "Bunin, Nancy"
705 results on '"Bunin, Nancy"'

203. Phase I study of tandem high‐dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study

Author

Gilman, Andrew L., primary, Jacobsen, Chad, additional, Bunin, Nancy, additional, Levine, John, additional, Goldman, Fred, additional, Bendel, Anne, additional, Joyce, Michael, additional, Anderson, Peter, additional, Rozans, Marta, additional, Wall, Donna A., additional, MacDonald, Tobey J., additional, Simon, Steve, additional, and Kadota, Richard P., additional

Published
2010
Full Text
View/download PDF

204. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

Author

Niemeyer, Charlotte M, primary, Kang, Michelle W, additional, Shin, Danielle H, additional, Furlan, Ingrid, additional, Erlacher, Miriam, additional, Bunin, Nancy J, additional, Bunda, Severa, additional, Finklestein, Jerry Z, additional, Sakamoto, Kathleen M, additional, Gorr, Thomas A, additional, Mehta, Parinda, additional, Schmid, Irene, additional, Kropshofer, Gabriele, additional, Corbacioglu, Selim, additional, Lang, Peter J, additional, Klein, Christoph, additional, Schlegel, Paul-Gerhard, additional, Heinzmann, Andrea, additional, Schneider, Michaela, additional, Starý, Jan, additional, van den Heuvel-Eibrink, Marry M, additional, Hasle, Henrik, additional, Locatelli, Franco, additional, Sakai, Debbie, additional, Archambeault, Sophie, additional, Chen, Leslie, additional, Russell, Ryan C, additional, Sybingco, Stephanie S, additional, Ohh, Michael, additional, Braun, Benjamin S, additional, Flotho, Christian, additional, and Loh, Mignon L, additional

Published
2010
Full Text
View/download PDF

206. Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease

Author

Walters, Mark C., primary, Hardy, Karen, additional, Edwards, Sandie, additional, Adamkiewicz, Thomas, additional, Barkovich, James, additional, Bernaudin, Francoise, additional, Buchanan, George R., additional, Bunin, Nancy, additional, Dickerhoff, Roswitha, additional, Giller, Roger, additional, Haut, Paul R., additional, Horan, John, additional, Hsu, Lewis L., additional, Kamani, Naynesh, additional, Levine, John E., additional, Margolis, David, additional, Ohene-Frempong, Kwaku, additional, Patience, Melinda, additional, Redding-Lallinger, Rupa, additional, Roberts, Irene A.G., additional, Rogers, Zora R., additional, Sanders, Jean E., additional, Scott, J. Paul, additional, and Sullivan, Keith M., additional

Published
2010
Full Text
View/download PDF

207. A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graftversushost disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)

Author

Pulsipher, Michael A., primary, Wall, Donna A., additional, Grimley, Michael, additional, Goyal, Rakesh K., additional, Boucher, Kenneth M., additional, Hankins, Patricia, additional, Grupp, Stephan A., additional, and Bunin, Nancy, additional

Published
2009
Full Text
View/download PDF

210. Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to Chemotherapy

Author

Bunin, Nancy J., primary, Davies, Stella M., additional, Aplenc, Richard, additional, Camitta, Bruce M., additional, DeSantes, Kenneth B., additional, Goyal, Rakesh K., additional, Kapoor, Neena, additional, Kernan, Nancy A., additional, Rosenthal, Joseph, additional, Smith, Franklin O., additional, and Eapen, Mary, additional

Published
2008
Full Text
View/download PDF

218. Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

Author

Porter, David, primary, Levine, Bruce, additional, Bunin, Nancy, additional, Stadtmauer, Edward, additional, Luger, Selina, additional, Goldstein, Steven, additional, Schuster, Stephen, additional, Tsai, Donald, additional, Nasta, Sunita, additional, Loren, Alison, additional, Perl, Alexander, additional, Oliver, Julie, additional, Sohal, Ambika, additional, Veloso, Liz, additional, Emerson, Stephen, additional, and June, Carl, additional

Published
2004
Full Text
View/download PDF

226. Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)

Author

Milner, Jordan, Talano, Julie-An, Harrison, Lauren, Ayello, Janet, Flower, Allyson, Chu, Yaya, Rigot, Olivia, Johnson, Bryon D, Li, Yimei, Lee, Dean Anthony, Abu-Arja, Rolla, Chu, Julia, Dvorak, Christopher C., O’Donnell, Lynn C., Wang, Yongping, Bunin, Nancy J., and Cairo, Mitch S.

Published
2022
Full Text
View/download PDF

240. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Author

Pulsipher, Michael A., Carlson, Chris, Langholz, Bryan, Wall, Donna A., Schultz, Kirk R., Bunin, Nancy, Kirsch, Ilan, Gastier-Foster, Julie M., Borowitz, Michael, Desmarais, Cindy, Williamson, David, Kalos, Michael, and Grupp, Stephan A.

Abstract

Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)–MRD better identifies pre- and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children’s Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P < .0001), especially in the MRD negative cohort (relapse, 0% vs 16%; P = .02; 2-year overall survival, 96% vs 77%; P = .003). Post-HCT NGS-MRD detection was better at predicting relapse than MFC-MRD (P < .0001), especially early after HCT (day 30 MFC-MRD positive relapse rate, 35%; NGS-MRD positive relapse rate, 67%; P = .004). Any post-HCT NGS positivity resulted in an increase in relapse risk by multivariate analysis (hazard ratio, 7.7; P = .05). Absence of detectable IgH-V(D)J NGS-MRD pre-HCT defines good-risk patients potentially eligible for less intense treatment approaches. Post-HCT NGS-MRD is highly predictive of relapse and survival, suggesting a role for this technique in defining patients early who would be eligible for post-HCT interventions. The trial was registered at www.clinicaltrials.gov as #NCT00382109.

Published
2015
Full Text
View/download PDF

246. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation

Author

Aplenc, Richard, Zhang, Mei-Jie, Sung, Lillian, Zhu, Xiaochun, Ho, Vincent T., Cooke, Kenneth, Dvorak, Christopher, Hale, Gregory, Isola, Luis M., Lazarus, Hillard M., McCarthy, Philip L., Olsson, Richard, Pulsipher, Michael, Pasquini, Marcelo C., and Bunin, Nancy

Abstract

The rising incidence of pediatric obesity may significantly affect bone marrow transplantation (BMT) outcomes. We analyzed outcomes in 3687 children worldwide who received cyclophosphamide-based BMT regimens for leukemias between 1990 and 2007. Recipients were classified according to age-adjusted body mass index (BMI) percentiles as underweight (UW), at risk of UW (RUW), normal, overweight (OW), or obese (OB). Median age and race were similar in all groups. Sixty-one percent of OB children were from the United States/Canada. Three-year relapse-free and overall survival ranged from 48% to 52% (P= .54) and 55% to 58% (P= .81) across BMI groups. Three-year leukemia relapses were 33%, 33%, 29%, 25%, and 21% in the UW, RUW, normal, OW, and OB groups, respectively (P< .001). Corresponding cumulative incidences for transplant-related mortality (TRM) were 18%, 19%, 21%, 22%, and 28% (P< .01). Multivariate analysis demonstrated a decreased risk of relapse compared with normal BMI (relative risk [RR] = 0.73; P< .01) and a trend toward higher TRM (RR = 1.28; P= .014). BMI in children is not significantly associated with different survival after BMT for hematologic malignancies. Obese children experience less relapse posttransplant compared with children with normal BMI; however, this benefit is offset by excess in TRM.

Published
2014
Full Text
View/download PDF

247. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Author

Pulsipher, Michael A., Langholz, Bryan, Wall, Donna A., Schultz, Kirk R., Bunin, Nancy, Carroll, William L., Raetz, Elizabeth, Gardner, Sharon, Gastier-Foster, Julie M., Howrie, Denise, Goyal, Rakesh K., Douglas, James G., Borowitz, Michael, Barnes, Yvonne, Teachey, David T., Taylor, Candace, and Grupp, Stephan A.

Abstract

Sirolimus has activity against acute lymphoblastic leukemia (ALL) in xenograft models and efficacy in preventing acute graft-versus-host disease (aGVHD). We tested whether addition of sirolimus to GVHD prophylaxis of children with ALL would decrease aGVHD and relapse. Patients were randomized to tacrolimus/methotrexate (standard) or tacrolimus/methotrexate/sirolimus (experimental). The study met futility rules for survival after enrolling 146 of 259 patients. Rate of Grade 2-4 aGVHD was 31% vs 18% (standard vs experimental, P = .04), however, grade 3-4 aGVHD was not different (13% vs 10%, P = .28). Rates of veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA) were lower in the nonsirolimus arm (9% vs 21% VOD, P = .05; 1% vs 10% TMA, P = .06). At 2 years, event free survival (EFS) and overall survival (OS) were 56% vs 46%, and 65% vs 55% (standard vs experimental), respectively (P = .28 and .23). Multivariate analysis showed increased relapse risk in children with ≥0.1% minimal residual disease (MRD) pretransplant, and decreased risk in patients with grades 1-3 aGVHD (P = .04). Grades 1-3 aGVHD were associated with improved EFS (P = .02), whereas grade 4 aGVHD and extramedullary disease at diagnosis led to inferior OS. Although addition of sirolimus decreased aGVHD, survival was not improved. This study is registered with ClinicalTrials.gov as #NCT00382109.

Published
2014
Full Text
View/download PDF

249. Reduced Intensity/Reduced Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute Gvhd

Author

Arnold, Danielle E., Nofal, Rofida, Wakefield, Connor, Lehmberg, Kai, Wustrau, Katharina, Albert, Michael H., Morris, Emma C., Heimall, Jennifer, Bunin, Nancy J., Kumar, Ashish, Jordan, Michael B., Cole, Theresa, Choo, Sharon, Brettig, Tim, Speckmann, Carsten, Ehl, Stephan, Salamonowicz-Bodzioch, Malgorzata, Wahlstrom, Justin, Rao, Kanchan, Booth, Claire, Worth, Austen J.J., and Marsh, Rebecca

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results